Aignostics Expands Atlas H&E-TME to Three New Cancer Types

We're excited to announce that Atlas H&E-TME now supports spatial TME analysis for three additional cancer types: pancreas, prostate, and stomach cancer. These join our existing coverage of bladder, breast, colorectum, liver, and lung, bringing Atlas H&E-TME to eight cancer types in total.

The expansion was driven by a clear goal: broader coverage of the most common cancers. Our initial five indications covered approximately 50% of invasive cancer cases. With the addition of prostate, pancreas, and stomach, that coverage grows to around 70% — making Atlas H&E-TME applicable to a wider range of oncology research and drug development programs. We plan to extend this further, targeting over 90% coverage of invasive cancer cases by the end of 2026.

As with every indication we support, these three cancer types underwent extensive benchmarking before release. We train on a wide range of biological variation, then conduct three levels of benchmarking: validation across diverse slide sources, cross-scanner testing to ensure robustness, and performance evaluation on out-of-distribution cohorts. Full validation metrics are available upon request here.

Alongside this expansion, we've continued to improve performance across our existing five indications, including enhancements to fine-grained structure detection and immune cell classification.

This is part of our ongoing commitment to expanding Atlas H&E-TME's coverage across oncology. More cancer types and features are on the way.

Learn more or request a free trial here.

Atlas H&E-TME is intended for research use only. Not for use in diagnostic procedures.